Foretinib (GSK1363089): ATP-Competitive Multikinase Inhibitor for Cancer Research

Executive Summary: Foretinib (GSK1363089) is a small-molecule, ATP-competitive inhibitor that targets multiple receptor tyrosine kinases, including VEGFRs, Met (HGFR), and others, with IC₅₀ values ranging from 0.4 to 9.6 nmol/L under standard in vitro assay conditions (Schwartz 2022). It suppresses tumor cell proliferation and migration by blocking HGF-induced signaling and induces G2/M cell cycle arrest in cancer cell lines. Foretinib exhibits potent anti-tumor effects in established xenograft models of ovarian cancer at 30 mg/kg oral dosing. The compound is intended for research use only and requires proper storage at -20°C to maintain stability (ApexBio). All claims are based on peer-reviewed experimental data and manufacturer documentation.

Biological Rationale

Receptor tyrosine kinases (RTKs) are central mediators of cell proliferation, motility, and survival in cancer. Dysregulation of RTKs such as vascular endothelial growth factor receptors (VEGFRs) and hepatocyte growth factor receptor (HGFR/Met) contributes to tumor growth, angiogenesis, and metastasis (Schwartz 2022). Foretinib (GSK1363089) was designed to inhibit multiple RTKs implicated in malignant progression, including Met, Ron, KDR (VEGFR2), Flt-1, Flt-4 (VEGFR3), KIT, Flt-3, PDGFRα/β, and Tie-2. This broad-spectrum inhibition disrupts key oncogenic signaling pathways and impairs tumor cell viability and dissemination.

Mechanism of Action of Foretinib (GSK1363089)

Foretinib is a potent, orally bioavailable ATP-competitive inhibitor that binds to the catalytic domains of targeted RTKs, preventing phosphorylation and downstream signaling. The compound demonstrates nanomolar inhibitory potency against purified kinase domains in biochemical assays (IC₅₀ = 0.4–9.6 nmol/L for primary targets) (Schwartz 2022). In cell-based assays, Foretinib inhibits cellular MET phosphorylation with an IC₅₀ of 21–23 nmol/L in A549 and HT29 cancer cell lines. Mechanistically, it blocks HGF-induced cell motility, induces G2/M cell cycle arrest, and reduces proliferation. In vivo, oral administration at 30 mg/kg significantly decreases metastatic tumor burden in ovarian cancer xenograft models. The compound is soluble at ≥31.65 mg/mL in DMSO but insoluble in water and ethanol, requiring specific handling for reproducible results (ApexBio).

Evidence & Benchmarks

• Foretinib inhibits Met, Ron, VEGFR2 (KDR), Flt-1, Flt-4, KIT, Flt-3, PDGFRα/β, and Tie-2, with IC₅₀ values ranging from 0.4 to 9.6 nmol/L in purified kinase assays (Schwartz 2022).
• In cellular models (A549 lung, HT29 colon, PC-3 prostate, B16F10 melanoma), Foretinib achieves MET inhibition at 21–23 nmol/L and suppresses proliferation at low nanomolar concentrations (Schwartz 2022).
• Oral dosing of 30 mg/kg Foretinib in ovarian cancer xenografts reduces tumor nodules and total tumor weight, confirming in vivo efficacy (Schwartz 2022).
• Foretinib blocks HGF-induced cell migration and invasion in multiple cancer cell types, as measured by wound healing and transwell assays (Schwartz 2022).
• Compound stability is optimal at -20°C in DMSO; aqueous or ethanol-based solutions result in precipitation or loss of potency (ApexBio).

Compared to prior summaries such as "Foretinib: Multikinase Inhibitor for Advanced Cancer Research", which reviews overall utility, this article provides updated, quantitative assay data and tighter linkage to peer-reviewed benchmarks.

For a mechanistic deep-dive, see this mechanistic dissection; our article uniquely quantifies IC₅₀ values and workflow parameters.

Applications, Limits & Misconceptions

Foretinib (GSK1363089) is used to dissect VEGF and HGF/Met signaling in cancer research, particularly for screening tumor cell growth, migration, and invasion in vitro and in vivo. The compound is not approved for diagnostic, therapeutic, or clinical applications. All uses are limited to preclinical research. Its broad-spectrum activity makes it suitable for multi-pathway studies, but specificity for individual kinases should be independently confirmed in each cell context.

Common Pitfalls or Misconceptions

• Foretinib is not selective for a single kinase; off-target effects may confound pathway attribution in complex models.
• It is not water- or ethanol-soluble; improper solvents lead to precipitation and reduced activity.
• The compound degrades rapidly above -20°C or with repeated freeze-thaw cycles; always prepare and store aliquots.
• Not suitable for clinical or diagnostic use—intended strictly for research applications.
• Some cell lines may exhibit variable sensitivity due to differential kinase expression; dose-response must be empirically determined.

Further clarification on experimental design can be found in "Foretinib (GSK1363089): Unraveling Cell Fate and Signal Integration", which expands on cell fate methodologies; this article updates with new benchmarked protocols and warnings.

Workflow Integration & Parameters

Recommended use involves preparing stock solutions in DMSO at ≥31.65 mg/mL, storing at -20°C, and aliquoting to avoid degradation. For in vitro assays, dilute stocks into assay buffers immediately prior to use, keeping final DMSO concentration below 0.1% v/v. IC₅₀ determinations should be repeated for each cell line and endpoint (e.g., proliferation, migration, invasion, phosphorylation status). In vivo, dosing regimens of 30 mg/kg by oral gavage are supported by xenograft efficacy studies. Foretinib (GSK1363089) is best employed in multi-parametric assays alongside fractional and relative viability endpoints (Schwartz 2022).

For product details and ordering, visit the Foretinib (GSK1363089) product page (A2974).

Conclusion & Outlook

Foretinib (GSK1363089) is a validated ATP-competitive inhibitor with robust activity against VEGFR, Met, and related RTKs, enabling precise interrogation of oncogenic signaling and tumor cell behavior in research models. Its nanomolar potency, broad kinase coverage, and well-defined application protocols make it a premier tool for advanced cancer research. Ongoing studies may further refine its use in combinatorial and pathway-dissection experiments, but current evidence strongly supports its role as a reference multikinase inhibitor in the field (Schwartz 2022).